First Parkinson’s Patients Treated in Landmark Phase 2 Trial of Dapansutrile – Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases
NEW YORK, March 24, 2026 /PRNewswire/ — Olatec Therapeutics, Inc. (“Olatec”), developing one of the most clinically advanced specific oral…